Summary
Rabbit immune sera raised against synthetic peptides of the HTLV-II envelope gp46 region were examined for HTLV-II neutralization ability by HTLV-vesicular stomatitis virus (VSV) pseudotype assay and syncytium inhibition assay. HTLV-II neutralization activity was detected in the sera against HTLV-II Env gp46, 80–103 but not in those to HTLV-II Env gp46, 171–196. Three rabbits immunized with the synthetic peptide of HTLV-II Env gp46, 80–103 and three non-immunized rabbits were challenged with intravenous inoculation of an HTLV-II-producing human cell line (MOT, 1×107 cells). The non-immunized rabbits showed seroconversion for HTLV-II after 2 weeks and maintained persistent infection but the immunized rabbits were protected from HTLV-II infection. Nested or repeated polymerase chain reaction revealed the presence of HTLV-II provirus sequences in the non-immunized rabbits but not in the immunized rabbits. These results suggest that peptide vaccination with a synthetic peptide corresponding to the HTLV-II neutralization region is useful for preventing HTLV-II infection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cockerell GL, Weiser MG, Rovnak J, Wicks-Beard B, Roberts B, Post A, Chen ISY, Lairmore MD (1991) Infectious transmission of human T-cell lymphotropic virus type II in rabbits. Blood 78: 1532–1537
Desgranges C, Souche S, Vernant JC, Smadja D, Vahlne A, Horal P (1994) Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera. AIDS Res Hum Retroviruses 10: 163–173
Dube DK, Sherman MP, Saksena NK, Bryz-Gornia V, Mendelson J, Love J, Arnold CB, Spicer T, Dube S, Glaser JB, Williams AE, Nishimura M, Jacobsen S, Ferrer JF, Derpino N, Quiruelas S, Poiesz BJ (1993) Genetic heterogeneity in human T-cell-leukemia/lymphoma virus type II. J Virol 67: 1175–1184
Hall WW, Takahashi H, Liu C, Kaplan MH, Scheewind O, Ijichi S, Nagashima K, Gallo RC (1992) Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol 66: 2456–2463
Hayashi K, Ohara N, Fujiwara K, Jeon HJ, Koirala TR, Takahashi K, Akagi T, Tomita N, Miyamoto K (1992) HTLV-II-specific antisera raised in rabbits immunized with a synthetic peptide of HTLV-II envelope protein. Virchows Arch B Cell Pathol Incl Mol Pathol 63: 37–41
Hayashi K, Ohara N, Fujiwara K, Aoki H, Jeon HJ, Takahashi K, Tomita N, Miyamoto K, Akagi T (1993) Co-expression of CD4 and CD8 associated with elevated interleukin-4 in a cord T cell line derived by cocultivating normal cord leukocytes and an HTLV-II-producing simian leukocyte cell line (Si-IIA). J Cancer Res Clin Oncol 119: 137–141
Hoshino H, Nakamura T, Tanaka Y, Miyoshi I, Yanagihara R (1993) Functional conservation of the neutralizing domains on the external envelope glycoprotein of cosmopolitan and melanesian strains of human T cell leukemia/lymphoma virus type I. J Infect Dis 168: 1368–1373
Ijichi S, Zaninovic V, Leon-S FE, Katahira Y, Sonoda S, Miura T, Hayami M, Hall WW (1993) Identification of human T cell leukemia virus type IIb infection in the Wayu, an aboriginal population of Colombia. Jpn J Cancer Res 84: 1215–1218
Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Blayney D, Golde D, Gallo RC (1982) A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218: 571–573
Kalyanaraman VS, Narayanan R, Feorino P, Ramsey RB, Palmer EL, Chorba T, McDougal S, Getchell JP, Holloway B, Harrison AK, Cabradilla CD, Telfer M, Evatt B (1985) Isolation and characterization of a human T cell leukemia virus type II from a hemophilia-A patient with pancytopenia. EMBO J 4: 1455–1460
Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen ISY (1989) High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 244: 471–475
Loughran TP Jr, Coyle T, Sherman MP, Starkebaum G, Ehrlich GD, Ruscetti FW, Poiesz BJ (1992) Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood 80: 1116–1119
Morishita N, Ishii K, Tanaka Y, Sawada T, Hoshino H, Foung SKH, Miyoshi I (1994) Immunoglobulin prophylaxis against human T cell lymphotropic virus type II in rabbits. J Infect Dis 169: 620–623
Nakamura H, Hayami M, Ohota Y, Ishikawa K, Tsujimoto H, Kiyokawa T, Yoshida M, Sasagawa A, Honjo S (1987) Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer 40: 403–407
Ohara N, Hayashi K, Takahashi K, Miyamoto K, Akagi T (1993) A novel monoclonal antibody specifically reactive with human T-lymphotropic virus type-II (HTLV-II) envelope protein. Int J Cancer 54: 858–861
Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, Fletcher MA (1990) HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 335: 1439–1441
Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, Mcadams MW, Mcknight A, Clapham PR, Weiss RA, Haynes BF (1992) Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 66: 5879–5889
Rosenblatt JD, Golde DW, Wachsman W, Giorgi JV, Jacobs A, Schmidt GM, Quan S, Gasson JC, Chen ISY (1986) A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med 315: 372–377
Shimotohno K, Takahashi Y, Shimizu N, Gojobori T, Golde DW, Chen ISY, Miwa M, Sugimura T (1985) Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II. an open reading frame for the protease gene. Proc Natl Acad Sci USA 82: 3101–3105
Tanaka Y, Zeng L, Shiraki H, Shida H, Tozawa H (1991) Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol 147: 354–360
Tanaka Y, Tanaka R, Hoshino H (1994) Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-Leukemia virus-Type-II (HTLV-II). Int J Cancer 59: 655–660
Zucker-Franklin D, Hooper WC, Evatt BL (1992) Human lymphotropic retroviruses associated with mycosis fungoides: evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease. Blood 80: 1537–1545
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kariya, N., Hayashi, K., Hoshino, H. et al. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region. Archives of Virology 141, 471–480 (1996). https://doi.org/10.1007/BF01718311
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01718311